Afference develops the Phantom, a wireless haptic glove that uses neural stimulation to create artificial touch sensations, allowing users to feel digital interactions without physical contact. This technology enhances user experience in virtual, augmented, and mixed reality environments by bridging the gap between the digital and physical worlds.

AIRNA is developing RNA editing therapies to treat rare and common diseases by precisely modifying RNA sequences to correct genetic mutations. This approach aims to enhance patient health outcomes by targeting the underlying causes of genetic disorders.

Axonis Therapeutics is developing first-in-class oral KCC2 potentiator drugs, specifically targeting the KCC2 protein to restore functional inhibition in the brain. This approach aims to address neurological disorders such as epilepsy and pain by enhancing inhibitory signaling within the central nervous system.

Cytovale has developed the IntelliSep test, an FDA-cleared diagnostic tool that analyzes the biomechanical properties of white blood cells from a standard blood draw to assess a patient's risk of sepsis within 8 minutes. This rapid detection addresses the critical challenge of timely diagnosis in sepsis, a condition that increases mortality by 8% for every hour treatment is delayed.

Dimension Inx develops biomaterials that create regenerative microenvironments to enhance cell functionality and restore organ function. Their technology addresses the limitations of traditional cell therapies by providing a three-dimensional matrix that promotes vascular integration and durable therapeutic responses.

IpiNovyx Bio develops best-in-class proteasome inhibitors targeting cancer, autoimmune, and inflammatory diseases. The company advances a new class of highly selective and reversible immunoproteasome inhibitors based on proprietary discovery technology. This focus aims to create safer and more effective treatments by targeting the proteasome pathway.

miRecule is developing Antibody RNA Conjugate (ARC) therapeutics using its proprietary DREAmiR™ platform, which leverages genomic patient data to create targeted RNA therapies for cancer and muscular dystrophy. The company addresses genetic abnormalities by designing tailored therapeutics that aim to alleviate the debilitating symptoms associated with these disorders.

Modifibio discovers and develops novel therapeutics for cardiometabolic and respiratory diseases using a proprietary macrocyclic peptide platform that delivers high affinity and selectivity for difficult protein targets. The company runs an integrated end‑to‑end drug development pipeline—from target identification and preclinical validation to IND filing and Phase I‑III clinical trials—while collaborating with academic and industry partners to expand its research capabilities.

Ochre Bio develops a deep phenotyping platform that utilizes human models to generate genomic and phenotypic data at scale, enabling the rapid development of RNA therapies for chronic liver disease. This approach addresses the rising prevalence of liver disease, which is a leading cause of premature death globally, by providing targeted treatments for patients with late-stage conditions.

RA UNLIMITED harnesses solar photovoltaic technology to generate clean and affordable electricity for homes, businesses, and communities in the Philippines. The company addresses the reliance on fossil fuels by providing sustainable energy solutions that create jobs and enhance the quality of life for Filipinos.

Scioto develops an Activated Bacterial Therapeutics platform that enhances the delivery and efficacy of live bacterial therapeutics by leveraging biofilm formation to optimize gut health. Their technology specifically targets gastrointestinal disorders and autism spectrum disorder, addressing unmet medical needs through improved therapeutic interactions within the gut-brain axis.

Simergent is developing the Archimedes automated peritoneal dialysis system, designed to enhance patient mobility and comfort by utilizing lower filling and draining pressures while maintaining precise volume control. This device addresses the challenges of current home dialysis systems, which are often cumbersome and associated with high rates of peritonitis, allowing patients to engage in daily activities without frequent clinic visits.